Suvannavejh: The obesity space has become a major focus for investors

Summary

Mizuho analyst Graig Suvannavejh says the obesity space remains a major focus for investors, driven by the effectiveness of GLP-1 drugs and upcoming oral versions. He expects large pharmaceutical companies facing patent cliffs to continue acquiring smaller biotech companies with mid- or late-stage assets to replace lost revenue. Key M&A areas include oncology, inflammatory and immune diseases, and neurology, with rumors of deals involving Eli Lilly, Merck, and others.

• Obesity and GLP-1 drugs remain a major investor theme.
• Oral GLP-1 versions are expected to drive continued interest.
• Pfizer's roughly $10 billion obesity acquisition highlights recent M&A activity.
• Patent cliffs are pushing large pharma to seek new revenue through M&A.
• Biotech companies with mid-stage, late-stage, or commercial assets are key targets.
• Oncology, immunology, and neurology are cited as high unmet-need M&A areas.
• Rumors include Eli Lilly eyeing a French biotech and Merck eyeing Revolution Medicines.
• A major healthcare conference is starting, with obesity and M&A as key themes.